Compare HSBC Holdings plc (HSBC) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HSBC Holdings plc vs Mesoblast Limited — how do they compare? HSBC Holdings plc trades at $104.21 (market cap $353.82B), while Mesoblast Limited trades at $16.87 (market cap $2.21B). The key difference: HSBC Holdings plc is far larger — about 160.1× Mesoblast Limited's market cap, and HSBC Holdings plc pays a 3.63% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| HSBC | MESO | |
|---|---|---|
Market Cap | $353.82B | $2.21B |
Sector | Technology | Technology |
52-Week High | $107.86 | $20.96 |
52-Week Low | $63.84 | $12.88 |
Dividend Yield | 3.63% | — |
Enterprise Value | — | $2.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HSBC's stock trades at $103.88, up 0.54% today, with a bullish technical signal from moving averages and support near $103. Recent Q2 2026 earnings beat expectations with a 7% revenue rise to $19 billion (Defense World, 2026-08-06), and the company announced a $1 billion buyback (WSJ, 2026-08-04). Valuation metrics include a P/E of 14.74 and ROE of 12.44%, reflecting solid profitability.
The outlook is positive due to strong earnings momentum and shareholder returns, but risks include a recent analyst downgrade (Citi to 'neutral' on August 5, 2026) and exposure to Asian market volatility. With 38.1% of analysts rating it a buy, the stock offers growth potential tempered by competitive and regulatory headwinds.
MESO trades at $16.9, up 1.32% on the day, with a bullish technical signal from moving averages. The company reported Ryoncil net revenues of $36 million for the quarter ended June 30, 2026, and achieved its target of 300 patients in a Phase 3 trial for chronic low back pain. Despite strong revenue growth from its commercial launch, fundamentals show a net income margin of -144.33% and negative EBITDA of $80.06 million for 2025, reflecting significant losses amid expansion.
The outlook hinges on commercial execution and regulatory progress, with analyst consensus leaning buy (45% buy ratings). Key risks include high cash burn, dependence on pipeline success, and competitive pressures. Upside potential exists if revenue growth accelerates and losses narrow, but investors face volatility from clinical trial outcomes and funding needs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
